Christopher R. Stone

Array ( [id] => 13117869 [patent_doc_number] => 10077277 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-18 [patent_title] => Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors [patent_app_type] => utility [patent_app_number] => 14/735438 [patent_app_country] => US [patent_app_date] => 2015-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24556 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 183 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14735438 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12346752 [patent_doc_number] => 09951087 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-24 [patent_title] => Fused ring analogues of anti-fibrotic agents [patent_app_type] => utility [patent_app_number] => 14/730753 [patent_app_country] => US [patent_app_date] => 2015-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 11 [patent_no_of_words] => 22379 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14730753 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10554744 [patent_doc_number] => 09278940 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-08 [patent_title] => 'Cyclic amines as bromodomain inhibitors' [patent_app_type] => utility [patent_app_number] => 14/729959 [patent_app_country] => US [patent_app_date] => 2015-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41098 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14729959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10373024 [patent_doc_number] => 20150258031 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-17 [patent_title] => 'MODIFIED RELEASE FORMULATIONS OF MEMANTINE ORAL DOSAGE FORMS' [patent_app_type] => utility [patent_app_number] => 14/722538 [patent_app_country] => US [patent_app_date] => 2015-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 10927 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14722538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11727913 [patent_doc_number] => 20170189357 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-06 [patent_title] => 'METHODS OF LIMITING MORBIDITY IN HEMOGLOBINOPATHIES' [patent_app_type] => utility [patent_app_number] => 15/313689 [patent_app_country] => US [patent_app_date] => 2015-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 13781 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15313689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11727966 [patent_doc_number] => 20170189409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-06 [patent_title] => 'MEDICAL USE' [patent_app_type] => utility [patent_app_number] => 15/313722 [patent_app_country] => US [patent_app_date] => 2015-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 15946 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15313722 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11074158 [patent_doc_number] => 20160271122 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-22 [patent_title] => 'COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/708891 [patent_app_country] => US [patent_app_date] => 2015-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 68963 [patent_no_of_claims] => 139 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14708891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11002391 [patent_doc_number] => 20160199340 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-14 [patent_title] => 'CALEBIN A FOR HEPATIC STEATOSIS' [patent_app_type] => utility [patent_app_number] => 14/690438 [patent_app_country] => US [patent_app_date] => 2015-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 9459 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14690438 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10567591 [patent_doc_number] => 09290750 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-22 [patent_title] => '7,11-methanocycloocta [b] quinoline derivative as highly functionalizable acetylcholinesterase inhibitors' [patent_app_type] => utility [patent_app_number] => 14/669160 [patent_app_country] => US [patent_app_date] => 2015-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29620 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14669160 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10387901 [patent_doc_number] => 20150272908 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-01 [patent_title] => 'HALOGENATED DIARYLACETYLENES AND METHODS OF TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 14/668865 [patent_app_country] => US [patent_app_date] => 2015-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 6018 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14668865 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10699357 [patent_doc_number] => 20160045504 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-18 [patent_title] => 'COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA' [patent_app_type] => utility [patent_app_number] => 14/665600 [patent_app_country] => US [patent_app_date] => 2015-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 9686 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14665600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11514626 [patent_doc_number] => 20170081700 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-23 [patent_title] => 'METHODS FOR SCREENING FOR INHIBITORS OF COMPLEMENT SERINE PROTEASES' [patent_app_type] => utility [patent_app_number] => 15/125367 [patent_app_country] => US [patent_app_date] => 2015-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 12029 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15125367 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10373077 [patent_doc_number] => 20150258082 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-17 [patent_title] => 'COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS' [patent_app_type] => utility [patent_app_number] => 14/657584 [patent_app_country] => US [patent_app_date] => 2015-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 25437 [patent_no_of_claims] => 71 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14657584 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10361016 [patent_doc_number] => 20150246021 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-03 [patent_title] => 'PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 14/639934 [patent_app_country] => US [patent_app_date] => 2015-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 16804 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14639934 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11348792 [patent_doc_number] => 20160367532 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-22 [patent_title] => 'ENDOPARASITE CONTROL AGENT' [patent_app_type] => utility [patent_app_number] => 15/120765 [patent_app_country] => US [patent_app_date] => 2015-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10181 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15120765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10289116 [patent_doc_number] => 20150174114 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-25 [patent_title] => 'METHODS FOR THE TREATMENT OF NON-HODGKIN\'S LYMPHOMAS USING LENALIDOMIDE, AND GENE AND PROTEIN BIOMARKERS AS A PREDICTOR' [patent_app_type] => utility [patent_app_number] => 14/636949 [patent_app_country] => US [patent_app_date] => 2015-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 20683 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14636949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10289159 [patent_doc_number] => 20150174157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-25 [patent_title] => 'INHALED NO DONOR PIPERAZINYL DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION BY REDUCING VEGF AND RESTORING eNOS IN HYPOXIC PULMONARY ARTERY' [patent_app_type] => utility [patent_app_number] => 14/634440 [patent_app_country] => US [patent_app_date] => 2015-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 16511 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14634440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13675089 [patent_doc_number] => 20160376278 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-29 [patent_title] => FUSED PYRAZOLE DERIVATIVE HAVING AUTOTAXIN INHIBITORY ACTIVITY [patent_app_type] => utility [patent_app_number] => 15/120763 [patent_app_country] => US [patent_app_date] => 2015-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31558 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 975 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15120763 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11751548 [patent_doc_number] => 09709557 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-07-18 [patent_title] => 'Anthraquinone based near IR emitting compounds and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/632168 [patent_app_country] => US [patent_app_date] => 2015-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 11 [patent_no_of_words] => 14078 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14632168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10354877 [patent_doc_number] => 20150239881 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-27 [patent_title] => 'HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/626749 [patent_app_country] => US [patent_app_date] => 2015-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 54390 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14626749 [rel_patent_id] =>[rel_patent_doc_number] =>)